Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OL-CD19-GDT in Relapsed/Refractory Systemic Sclerosis and Primary Sjogren's Syndrome
NCT07167537Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OL-CD19-GDT in systemic sclerosis (SSc), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 30 days and Treatment emergent adverse event at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
OL-CD19-GDT
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07167537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167537.